Oxitropium Bromide - CAS 30286-75-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Oxitropium bromide, a quaternary ammonium congener of hyoscine with anticholinergic properties, is an mAChR antagonist used for the treatment of asthma and chronic obstructive pulmonary disease.
(8r)-6 beta,7 beta-epoxy-8-ethyl-3 alpha((-)-tropoyl)-1 alpha H, 5 alpha H-tropanium bromide; Ba 253; Ba 253Br; Ba-253; Ba-253Br; oxitropium; oxitropium bromide; oxitropium iodide, (R)-isomer; oxitropium iodide, (S)-isomer; Oxivent; oxytropium bromide; Tersigat; Ventilat
Store in a cool and dry place (or refer to the Certificate of Analysis).
Melting Point:
203-204 ℃ (decomp)
Canonical SMILES:
1.Use of inhaled anticholinergic agents in obstructive airway disease.
Restrepo RD Respir Care. 2007 Jul;52(7):833-51.
In the last 2 decades, anticholinergic agents have been generally regarded as the first-choice bronchodilator therapy in the routine management of stable chronic obstructive pulmonary disease (COPD) and, to a lesser extent, asthma. Anticholinergics are particularly important bronchodilators in COPD, because the vagal tone appears to be the only reversible component of airflow limitation in COPD. The inhaled anticholinergics approved for clinical use are synthetic quaternary ammonium congeners of atropine, and include ipratropium bromide, oxitropium bromide, and tiotropium bromide. This article reviews the most current evidence for inhaled anticholinergics in obstructive airway disease and summarizes outcomes reported in randomized controlled trials.
2.Comparison of the bronchodilating effect of oxitropium bromide and fenoterol in asthmatic children.
Van Bever HP;Desager KN;Pauwels JH;Vermeire PA Eur J Pediatr. 1994 Aug;153(8):604-6.
Using a randomized double blind study design, the bronchodilating effect of 200 micrograms inhaled oxitropium bromide (OB) was compared with 200 micrograms inhaled fenoterol (F) after an interval of 20 min, in 20 asthmatic children aged 12.7 years (range: 4.9-15.1 years), suffering from mild bronchoconstriction (mean forced expiratory volume during ls: 73.4%, range: 51%-85%). Both drugs induced a comparable degree of bronchodilatation and no significant differences were found between the OB group and the F group, suggesting equipotency for both drugs after a 20 min interval, at the 200 micrograms dose level. Furthermore, a significant improvement of lung function parameters was detected in both groups after subsequent administration of 400 micrograms F, indicating that inhalation of 200 micrograms of OB or F results in submaximal bronchodilation in asthmatic children suffering from mild bronchoconstriction.
3.Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with COPD or asthma.
Taube C;Kanniess F;Grönke L;Richter K;Mücke M;Paasch K;Eichler G;Jörres RA;Magnussen H Respir Med. 2003 May;97(5):568-77.
The aim of the present study was to assess the reproducibility of changes in forced inspiratory volumes after bronchodilator inhalation. Thirteen patients with chronic obstructive pulmonary disease (COPD) (FEV1, 32-75%pred) and 10 patients with asthma (FEV1, 43-75%pred) inhaled either 200 microg fenoterol or 200 microg oxitropium bromide or placebo, each of them on three occasions, on nine different days in a randomised, cross-over, double-blind fashion. Forced expiratory (FEV1) and inspiratory (FIV1) volumes were measured before and 30 min after inhalation. In patients with COPD, the increase in FEV1 (coefficient of variation) was 221 ml (43%) after fenoterol and 235 ml (33%) after oxitropium; changes in FIV1 were 301 ml (45%) and 360 ml (29%). In patients with asthma, FEV1 improved by 618 ml (26%) and 482 ml (25%), FIV1 by 553 ml (41%) and 475 ml (23%). In less severe COPD or asthma, the reduction in dyspnoea was associated with the improvements in both FIV1 and FEV1, but in severe COPD with the improvement in FIV1 only. The data demonstrate that, at least in terms of relative changes, the reproducibility of bronchodilator responses in terms of FIV1 is similar to that of FEV1 and they underline the assertion of FIV1 being a sensible parameter particularly in severe COPD.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mAChR Products

CAS 136152-65-3 (S)-(+)-Dimethindene Maleate

(S)-(+)-Dimethindene Maleate
(CAS: 136152-65-3)

The maleate salt form of (S)-(+)-Dimethindene, which has been found to be a subtype-selective mAChR M2 antagonist and histamine H1 receptor antagonist.

CAS 96487-37-5 Nuvenzepine

(CAS: 96487-37-5)

Nuvenzepine, a new pirenzepine-analog, is an mAChR antagonist, administered intraduodenally, displayed a long-lasting and dose-dependent inhibition of neostigmi...

CAS 23062-91-1 PD 102807

PD 102807
(CAS: 23062-91-1)

PD 102807 is a selective mAChR M4 antagonist with IC50 values of 91, 6559, 3441, 95 and 7412 nM for human M4, M1, M2, M3, and M5 receptors respectively.

CAS 560083-42-3 AC260584

(CAS: 560083-42-3)

AC260584 is a potent and selective muscarinic M₁ receptor allosteric agonist (pEC50= 7.6). Studies indicated that AC260584 has a behavioral profile consistent w...

CAS 1160247-92-6 VU 0238429

VU 0238429
(CAS: 1160247-92-6)

VU 0238429 is a selective positive allosteric modulator of M5 muscarinic acetylcholine receptor (EC50 = 1.16, >30 and >30 μM at M5, M1 and M3 receptors, respect...

CAS 120241-31-8 Alvameline

(CAS: 120241-31-8)

Alvameline, also known as Lu25-109, is a partial M1agonist and M2/M3antagonist that was progressed into clinical studies for the treatment of Alzheimer's diseas...

CAS 89430-38-6 [D-Trp 7,9,10]-Substance P

[D-Trp 7,9,10]-Substance P
(CAS: 89430-38-6)

[D-Trp 7,9,10]-Substance P is a substance P analog that blocks activation of Gq/11 by M1 muscarinic ACh receptors. Does not inhibit Gi/o activation by M2 ACh re...

CAS 80-49-9 Homatropine Methylbromide

Homatropine Methylbromide
(CAS: 80-49-9)

Homatropine Methylbromide is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM an...

Chemical Structure

CAS 30286-75-0 Oxitropium Bromide

Quick Inquiry

Verification code

Featured Items